APTITUDE HEALTH®

EPICS

Conference Coverage: SABCS 2022 Highlights

Full Report

December 13, 2022

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
December 13, 2022



DISEASE-STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in breast cancer

- 8 from the US
- 3 from Europe

BREAST CANCER-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 8 US and 3 European Breast Cancer Experts

EPICS

Peter A. Kaufman, MD
University of Vermont Cancer Center

Priyanka Sharma, MD
University of Kansas Cancer Center

Mark Pegram, MD
Stanford University School of Medicine

Joyce A. O'Shaughnessy, MD
Baylor Scott & White Charles A. Sammons Cancer Center

CHAIR:
Adam Brufsky, MD, PhD
University of Pittsburgh School of Medicine

Guy Jerusalem, MD, PhD
Sart-Tilman University Hospital

Giuseppe Curigliano, MD, PhD
University of Milano/European Institute of Oncology

Pat Whitworth, MD, FACS, FSSO
Nashville Breast Center

Mary E. Cianfrocca, DO, FACP
City of Hope Comprehensive Cancer Center

Peter Beitsch, MD
Dallas Surgical Group

Javier Cortés, MD, PhD
International Breast Cancer Center

APTITUDE HEALTH®

Meeting Agenda (1/2)

EPICS

Time (EST)	Topic	Speaker/Moderator
10.00 AM – 10.05 AM	Welcome and Introductions	Adam Brufsky, MD, PhD
10.05 AM – 10.15 AM	**New and Emerging Treatments in HER2+ BC**	Giuseppe Curigliano, MD, PhD
10.15 AM – 10.35 AM	Discussion: New and Emerging Treatments in HER2+ BC	All
10.35 AM – 10.40 AM	Summary of Key Takeaways	Giuseppe Curigliano, MD, PhD
10.40 AM – 10.55 AM	**Clinical Utility of Genomic and Molecular Assays in BC Care**	Pat Whitworth, MD, FACS, FSSO
10.55 AM – 11.20 AM	Discussion: Clinical Utility of Genomic and Molecular Assays in BC Care	All
11.20 AM – 11.25 AM	Summary of Key Takeaways	Pat Whitworth, MD, FACS, FSSO
11.25 AM – 11.30 AM	Break	
11.30 AM – 11.40 AM	**New and Emerging Approaches in HR+, HER2– Early BC**	Guy Jerusalem, MD, PhD
11.40 AM – 11.50 AM	**New and Emerging Approaches in HR+, HER2– Metastatic BC**	Javier Cortés, MD, PhD
11.50 AM – 12.15 PM	Discussion: New and Emerging Approaches in Early and Metastatic HR+, HER2– BC	All
12.15 PM – 12.20 PM	Summary of Key Takeaways	Guy Jerusalem, MD, PhD, and Javier Cortés, MD, PhD

Meeting Agenda (2/2)

EPICS

Time (EST)	Topic	Speaker/Moderator
12.20 PM – 12.30 PM	**Maximizing Potential Targeting of HER2 in HER2-Low BC**	Mark Pegram, MD
12.30 PM – 12.45 PM	Discussion: Maximizing Potential Targeting of HER2 in HER2-Low BC	All
12.45 PM – 12.50 PM	Key Takeaways	Mark Pegram, MD
12.50 PM – 1.00 PM	**Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC)**	Peter Kaufman, MD
1.00 PM – 1.25 PM	Discussion: Advances in Early and Metastatic TNBC	All
1.25 PM – 1.30 PM	Key Takeaways	Peter Kaufman, MD
1.30 PM	Meeting Close	Adam Brufsky, MD, PhD

APTITUDE HEALTH®

EPICS

Clinical Utility of Genomic and Molecular Assays in BC Care

Clinical Utility of Genomic and Molecular Assays in BC Care

EPICS

Abstracts assigned*

Predictor of recurrence

- GS1-06. Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial. O'Regan R,

[illegible]

APTITUDE HEALTH®

*The abstracts that are not included in the following slides were not discussed during the meeting.

Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

O'Regan R, et al. #GS1-06

EPICS

BACKGROUND

> The SOFT trial in premenopausal breast cancer patients revealed that

APTITUDE HEALTH®

Utility of the 70-gene MammaPrint test for prediction of extended endocrine therapy benefit in patients with early-stage breast cancer in the IDEAL Trial

Liefers GJ, et al. #GS5-10

EPICS

BACKGROUND

> The IDEAL trial showed no significant benefit of 5 years of extended

Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating tumor DNA testing

Magbanua MJM, et al. #P5-05-01

EPICS

BACKGROUND

- Results using a tumor-informed sequencing assay for ctDNA detection of



APTITUDE HEALTH®

EPICS

Discussion Summary

Clinical Utility of Genomic and Molecular Assays in BC Care

Clinical Utility of Genomic and Molecular Assays in BC Care (1/3)

EPICS

Genomic assays

> The Breast Cancer Index (BCI) results of the SOFT trial (GS1-06) are considered confusing. *"One of the big mysteries of this meeting, I still*

Clinical Utility of Genomic and Molecular Assays in BC Care (2/3)

Genomic assays used by the experts

- In Spain, Oncotype is used

Clinical Utility of Genomic and Molecular Assays in BC Care (3/3)

EPICS

ctDNA

> Its potential applications are 1) as a predictive or real-time response marker for neoadjuvant or metastatic therapy, and 2) as an MRD assay for

[redacted]

APTITUDE HEALTH®

EPICS

New and Emerging Treatments in HER2+ BC

New and Emerging Treatments in HER2+ BC

EPICS

Abstracts assigned*

> GS2-01. Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously

[redacted]

*The abstracts that are not included in the following slides were not discussed during the meeting.

Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02

Krop I, et al, et al. #GS2-01

EPICS

BACKGROUND

> DESTINY-Breast02 (NCT03523585) is a phase III trial of T-DXd vs treatment of

Primary Endpoint: PFS by BICR

Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

Hurvitz SA, et al. #GS2-02

EPICS

BACKGROUND

> In the phase III DESTINY-Breast03 study, T-DXd demonstrated statistically

Updated Primary Endpoint: PFS by BICR

Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial

Janni W, et al. #PD18-07

EPICS

BACKGROUND

> This phase III trial investigates in patients with HR+, HER2+ mBC whether

Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant

Escrivá-de-Romani S, et al #PD18-10

EPICS

BACKGROUND

> Zanidatamab (zani) is a novel HER2-targeted bispecific antibody that

Table 3: Response Rates and DOR	Patients (N=36)[a]
cORR (CR + PR), n (%) (95% CI)	12 (33) (18.6, 51.0)

APTITUDE HEALTH®

EPICS

Discussion Summary

New and Emerging Treatments in HER2+ BC

New and Emerging Treatments in HER2+ BC (1/3)

EPICS

Second-line treatment of HER2+ mBC

- SOC in EU
  - In Italy, trastuzumab deruxtecan (T-DXd) was approved in November 2022 and can be considered the new SOC after progression on trastuzumab

New and Emerging Treatments in HER2+ BC (2/3)

EPICS

Treatment sequencing

> Sequencing trials need to be explored further, to understand how to achieve the best overall survival and preserve quality of life

[redacted]

New and Emerging Treatments in HER2+ BC (3/3)

EPICS

Interesting ongoing trials and agents

- DETECT V in triple-positive patients (PD-18-07) is regarded as an interesting trial, but it is not considered to be practice changing for the

APTITUDE HEALTH®

EPICS

New and Emerging Approaches in HR+, HER2– Early and Metastatic BC

New and Emerging Approaches in HR+, HER2– Early BC

EPICS

Abstracts assigned*

> GS1-09. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned

[redacted]

APTITUDE HEALTH®

*The abstracts that are not included in the following slides were not discussed during the meeting.

Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Johnston S, et al. #GS1-09

EPICS

IDFS Benefit in ITT Persists Beyond Completion of Abemaciclib

Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13)

Partridge AH, et al. #GS4-09

EPICS

BACKGROUND

STUDY POPULATION

OUTCOME

EXPERT CONCLUSIONS

BREAST CANCER OUTCOMES – POSITIVE & SOFT/TEXT

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Fasching PA, et al. #GS5-02

EPICS

Results: iDFS in the Overall Study Population

Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Isaacs C, et al. #GS5-03

EPICS

BACKGROUND

> I-SPY 2 is a multicenter, phase II trial using response-adaptive randomization



New and Emerging Approaches in HR+, HER2– Metastatic BC

EPICS

Abstracts assigned*

> GS3-06. Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer. Mayer EL, et al

*The abstracts that are not included in the following slides were not discussed during the meeting.

Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

Mayer EL, et al. #GS3-06

EPICS

BACKGROUND

[redacted]

Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

Turner NC, et al. #GS3-04

EPICS

BACKGROUND



EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Bardia A, et al. #GS3-01

EPICS

BACKGROUND

> In patients with ER+, HER2− mBC following progression on prior endocrine

Second interim analysis of overall survival (OS) from the TROPiCS-02 phase 3 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients with HR+/HER2- advanced breast cancer

Rugo HS, et al. #GS5-11

EPICS

BACKGROUND

APTITUDE HEALTH®

EPICS

Discussion Summary

New and Emerging Approaches in HR+, HER2– Early and Metastatic BC

New and Emerging Approaches in HR+, HER2– Early BC

EPICS

- The POSITIVE pregnancy trial (GS4-09), which allows treatment interruption for 2 years, is considered a potential "*game-changer*" for many

New and Emerging Approaches in HR+, HER2– Metastatic BC

EPICS

- The CAPItello-291 trial (GS3-04) could result in capivasertib replacing alpelisib, and will likely be practice-changing: ". . . *that's a registrational phase III*

APTITUDE HEALTH®

EPICS

Maximizing Potential Targeting of HER2 in HER2-Low BC

Maximizing Potential Targeting of HER2 in HER2-Low BC

EPICS

Abstracts assigned*

> GS2-03. TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast

[redacted]

*The abstracts that are not included in the following slides were not discussed during the meeting.

TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Hurvitz SA, et al. #GS2-03

EPICS

[redacted]

Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04

Harbeck N, et al. #P1-11-01

EPICS

APTITUDE HEALTH®

EPICS

Discussion Summary

Maximizing Potential Targeting of HER2 in HER2-Low BC

Maximizing Potential Targeting of HER2 in HER2-Low BC

EPICS

HER2 testing

> The emergence of HER2-low has raised many questions for pathologists regarding the accuracy of all archival IHC 1+ (HER2-low) and IHC 0

[redacted]

APTITUDE HEALTH®

EPICS

Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC)

Advances in Early and Metastatic TNBC

EPICS

Abstracts assigned*

Early TNBC

> GS5-01. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A

[redacted]

APTITUDE HEALTH®

*The abstracts that are not included in the following slides were not discussed during the meeting.

Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial

Gupta S, et al. #GS5-01

EPICS

BACKGROUND

ITT: Pathological Response to NACT by Rx-Arm

100

Primary results of SOLTI-1503 PROMETEO phase 2 trial of Combination of Talimogene Laherparepvec (T-VEC) with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy

Pascual T, et al. #PD11-04

EPICS

BACKGROUND

randomized phase 2 study – (ICML) Zhang #28

- Experts believe the resolution of molecular phenotype is possible in real time, and these vulnerabilities can potentially be targeted

Promising tolerability and efficacy results from dose-escalation in an ongoing phase I/II study of trovumtuzumab with polatuzumab vedotin for relapsed/refractory B-cell NHL – (ENHL) Ghosh #6222

- The regimen is seen as effective, exciting, safe, and broadly applicable to many patients

Mirzumetuzumab (mirzum) monotherapy for elderly/unfit patients with first-line DLBCL continues to show promising safety and efficacy with durable complete responses – (ENHL) Chamarelli #EP163

- This approach is seen as a great solution for a patient population in whom giving immunochemotherapy is difficult. It is viewed as effective and safe

FIRST-MIND: a phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed DLBCL – (ENHL) Bartlett #EP169

- Experts believe the combination of tafasitamab + lenalidomide with R-CHOP is safe. However, they would like to see phase III data to confirm its activity in this setting

Long-term analyses from L-MIND, a phase II study of tafasitamab plus lenalidomide (len) in patients with R/R DLBCL – (ICML) Duell #28

- The L-MIND regimen is seen as useful in the specific patient population with refractory disease. It was noted to be effective, very safe, and well tolerated. Some of the responses seen were clearly very durable

Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

Schmid P, et al. #PD11-09

EPICS

BACKGROUND

[redacted]

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Discussion Summary

Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC)

Advances in Early and Metastatic TNBC (1/3)

EPICS

- There were no practice-changing data presented at SABCS for TNBC
- It was noted that the TNBC category is biologically broader than currently defined. For example, the BluePrint assay

Advances in Early and Metastatic TNBC (2/3)

EPICS

Early TNBC

- The phase III trial (GS5-01) examining addition of carboplatin to paclitaxel neoadjuvant therapy in TNBC is regarded as

Advances in Early and Metastatic TNBC (3/3)

EPICS

mTNBC

- Although data are still early, the BEGONIA trial (PD11-09) is regarded as very interesting and supports the first-line usage

APTITUDE HEALTH®

US Headquarters
5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters
Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

aptitudehealth.com